McKesson — May 7, 2026 release

These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially. McKesson is establishing Fiscal 2027 Adjusted Earnings per Diluted Share guidance to $43.80 to $44.60. Long-Term Growth Targets McKesson continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes while driving sustainable value creation. The Company is reaffirming long-term Adjusted Earnings per Diluted Share growth targets of 13% to 16% as well as its long-term Adjusted Segment Operating Profit growth targets as follows: • North American Pharmaceutical of 5% to 8% • Oncology & Multispecialty of 13% to 16% • Prescription Technology Solutions of 10% to 13% Additional modeling considerations will be provided in the earnings call presentation. Conference Call Details McKesson has scheduled a conference call for today, Thursday, May 7, 2026, at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com . Upcoming Investor Event McKesson management will be participating in the BofA Securities 2026 Healthcare Conference on May 12, 2026. The audio webcasts, and a complete listing of upcoming events for the investment community, including details and updates, will be available on McKesson's Investor Relat